Combination chemotherapy with osimertinib for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding chemotherapy to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer that has not responded fully to osimertinib alone. It is for those whose cancer has a particular EGFR mutation and who still have detectable cancer DNA in their blood after starting osimertinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with advanced (stage IIIB, IIIC, or IV) lung adenocarcinoma, a type of non-small cell lung cancer
- Your cancer has an EGFR mutation (either exon 19 deletion or L858R) that is usually treated with osimertinib
- You have never had any previous treatment for advanced lung cancer (like chemotherapy, targeted therapy, or immunotherapy)
- You have a blood test that shows cancer DNA still present after about 3 weeks of osimertinib treatment
- You are generally in good health (able to do most daily activities) and have adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This Phase 2 trial tests whether adding chemotherapy can help people with EGFR-mutated lung cancer when their cancer-related blood test (liquid biopsy for EGFR DNA) is still positive after 3–4 weeks of starting osimertinib. It may help slow the cancer for longer by treating any remaining disease activity.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This trial tests a new combination of two drugs, osimertinib and etoposide, for people with lung cancer that has not responded well to osimertinib alone. The goal is to see if adding etoposide can help stop the cancer from growing.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.